BioMarin Pharmaceutical Company Profile (NASDAQ:BMRN)

About BioMarin Pharmaceutical (BMRN)

BioMarin Pharmaceutical logoBioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: BMRN
  • CUSIP: 09061G10
Key Metrics:
  • Previous Close: $89.58
  • 50 Day Moving Average: $90.54
  • 200 Day Moving Average: $88.38
  • 52-Week Range: $73.45 - $102.49
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -242.11
  • P/E Growth: -3.71
  • Market Cap: $15.49B
  • Outstanding Shares: 172,866,000
  • Beta: 1.58
Profitability:
  • Net Margins: -46.22%
  • Return on Equity: -8.54%
  • Return on Assets: -5.51%
Debt:
  • Debt-to-Equity Ratio: 0.25%
  • Current Ratio: 4.42%
  • Quick Ratio: 3.50%

Analyst Ratings

Consensus Ratings for BioMarin Pharmaceutical (NASDAQ:BMRN) (?)
Ratings Breakdown: 7 Hold Ratings, 13 Buy Ratings
Consensus Rating:Buy (Score: 2.65)
Consensus Price Target: $112.05 (25.09% upside)

Analysts' Ratings History for BioMarin Pharmaceutical (NASDAQ:BMRN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/15/2017Cowen and CompanyReiterated RatingOutperform$150.00LowView Rating Details
3/1/2017InstinetInitiated CoverageNeutral -> Neutral$93.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageNeutralN/AView Rating Details
2/27/2017WedbushReiterated RatingNeutral$102.00N/AView Rating Details
2/25/2017JPMorgan Chase & Co.Set Price TargetBuy$123.00N/AView Rating Details
2/10/2017GabelliReiterated RatingBuyN/AView Rating Details
2/7/2017Morgan StanleyInitiated CoverageOverweight$110.00N/AView Rating Details
1/23/2017Credit Suisse Group AGInitiated CoverageOutperform -> Outperform$111.00 -> $107.00N/AView Rating Details
1/9/2017Robert W. BairdSet Price TargetBuy$115.00N/AView Rating Details
11/29/2016Barclays PLCDowngradeOverweight -> Equal Weight$125.00 -> $105.00N/AView Rating Details
11/7/2016Piper Jaffray CompaniesDowngradeOverweight -> Neutral$105.00 -> $84.00N/AView Rating Details
11/3/2016Deutsche Bank AGInitiated CoverageBuy$106.00N/AView Rating Details
10/30/2016Royal Bank of CanadaSet Price TargetBuy$125.00N/AView Rating Details
10/13/2016Leerink SwannReiterated RatingOutperform$127.00N/AView Rating Details
10/7/2016Goldman Sachs Group IncUpgradeNeutralN/AView Rating Details
8/17/2016Jefferies Group LLCReiterated RatingBuyN/AView Rating Details
8/5/2016Stifel NicolausBoost Price TargetBuy$107.00 -> $113.00N/AView Rating Details
7/28/2016William BlairSet Price TargetBuy$116.00N/AView Rating Details
6/20/2016Oppenheimer Holdings Inc.Reiterated RatingMarket Perform$99.00N/AView Rating Details
4/7/2016BMO Capital MarketsInitiated CoverageOutperform$99.00N/AView Rating Details
1/15/2016Bank of America CorpReiterated RatingBuy$165.00 -> $135.00N/AView Rating Details
10/13/2015Raymond James Financial, Inc.Reiterated RatingOutperform$157.00N/AView Rating Details
8/4/2015SunTrust Banks, Inc.Reiterated RatingBuyN/AView Rating Details
6/18/2015Canaccord GenuityBoost Price TargetBuy$115.00 -> $150.00N/AView Rating Details
(Data available from 3/29/2015 forward)

Earnings

Earnings History for BioMarin Pharmaceutical (NASDAQ:BMRN)
Earnings by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)
Earnings History by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/26/2017        
2/23/2017Q416($0.38)($0.53)$296.54 million$300.00 millionViewN/AView Earnings Details
10/27/2016Q316($0.39)($0.26)$289.70 million$279.90 millionViewListenView Earnings Details
8/4/2016Q216($0.52)($2.61)$278.75 million$300.10 millionViewN/AView Earnings Details
4/28/2016Q116($0.85)($0.53)$240.21 million$236.70 millionViewListenView Earnings Details
2/25/2016Q415$0.67$0.39$224.14 million$227.90 millionViewListenView Earnings Details
10/29/2015Q315($0.65)($0.60)$216.32 million$208.90 millionViewListenView Earnings Details
8/3/2015Q215($0.53)($0.51)$218.16 million$250.50 millionViewN/AView Earnings Details
4/30/2015Q1($0.53)($0.43)$201.30 millionViewN/AView Earnings Details
2/25/2015Q414($0.59)($0.47)$189.01 million$230.90 millionViewN/AView Earnings Details
10/23/2014Q314($0.22)($0.16)$206.00 million$176.80 millionViewListenView Earnings Details
7/30/2014Q214($0.41)($0.23)$159.70 million$191.70 millionViewN/AView Earnings Details
5/1/2014($0.44)($0.01)$145.16 million$151.60 millionViewN/AView Earnings Details
2/26/2014Q413($0.35)($0.11)$146.07 million$146.90 millionViewN/AView Earnings Details
10/24/2013Q313($0.30)($0.38)$140.00 million$136.90 millionViewN/AView Earnings Details
7/25/2013Q2 2013($0.29)($0.16)$134.33 million$136.80 millionViewN/AView Earnings Details
4/25/2013Q1 2013($0.30)($0.31)$131.35 million$127.90 millionViewN/AView Earnings Details
2/21/2013Q4 2012($0.22)($0.43)$129.70 million$130.96 millionViewN/AView Earnings Details
10/25/2012($0.20)($0.04)ViewN/AView Earnings Details
8/1/2012($0.19)($0.27)ViewN/AView Earnings Details
4/26/2012($0.15)($0.21)ViewN/AView Earnings Details
2/16/2012($0.10)($0.23)ViewN/AView Earnings Details
10/27/2011($0.10)($0.16)ViewN/AView Earnings Details
7/28/2011($0.09)($0.05)ViewN/AView Earnings Details
4/28/2011($0.10)$0.14ViewN/AView Earnings Details
2/17/2011($0.02)($0.11)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for BioMarin Pharmaceutical (NASDAQ:BMRN)
Current Year EPS Consensus Estimate: $-0.95 EPS
Next Year EPS Consensus Estimate: $-0.37 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20166($2.51)($0.40)($0.94)
Q2 20166($4.02)($0.27)($2.11)
Q3 20166($0.63)($0.24)($0.41)
Q4 20165($0.67)($0.26)($0.50)
Q1 20173($0.38)($0.22)($0.32)
Q2 20174($0.35)($0.20)($0.27)
Q3 20173($0.25)($0.16)($0.22)
Q4 20174($0.27)($0.10)($0.20)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for BioMarin Pharmaceutical (NASDAQ:BMRN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for BioMarin Pharmaceutical (NASDAQ:BMRN)
Insider Ownership Percentage: 2.50%
Institutional Ownership Percentage: 97.78%
Insider Trades by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)
Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)
Insider Trades by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/16/2017Daniel K SpiegelmanCFOSell1,989$91.96$182,908.44View SEC Filing  
3/16/2017George Eric DavisEVPSell2,238$91.96$205,806.48View SEC Filing  
3/16/2017Jean Jacques BienaimeCEOSell10,000$91.69$916,900.00View SEC Filing  
3/10/2017Jean Jacques BienaimeCEOSell11,000$90.59$996,490.00View SEC Filing  
3/7/2017Jeffrey Robert AjerEVPSell5,000$90.56$452,800.00View SEC Filing  
3/6/2017Daniel K SpiegelmanCFOSell2,303$93.32$214,915.96View SEC Filing  
3/6/2017George Eric DavisEVPSell1,498$93.32$139,793.36View SEC Filing  
3/1/2017Daniel K SpiegelmanCFOSell35,000$94.07$3,292,450.00View SEC Filing  
3/1/2017V Bryan LawlisDirectorSell7,500$95.00$712,500.00View SEC Filing  
2/24/2017Henry J FuchsInsiderSell15,000$87.99$1,319,850.00View SEC Filing  
1/26/2017Jean Jacques BienaimeCEOSell10,000$84.22$842,200.00View SEC Filing  
1/11/2017Jean Jacques BienaimeCEOSell8,000$90.58$724,640.00View SEC Filing  
1/9/2017Daniel K SpiegelmanCFOSell5,000$90.00$450,000.00View SEC Filing  
1/9/2017Jean Jacques BienaimeCEOSell8,000$88.49$707,920.00View SEC Filing  
12/30/2016Jean Jacques BienaimeCEOSell8,000$83.60$668,800.00View SEC Filing  
11/22/2016Jean Jacques BienaimeCEOSell69,743$85.69$5,976,277.67View SEC Filing  
11/21/2016Jean Jacques BienaimeCEOSell69,744$87.56$6,106,784.64View SEC Filing  
11/8/2016Jean Jacques BienaimeCEOSell140,000$82.67$11,573,800.00View SEC Filing  
11/7/2016Jean Jacques BienaimeCEOSell70,000$82.52$5,776,400.00View SEC Filing  
10/28/2016Jean Jacques BienaimeCEOSell120,000$81.30$9,756,000.00View SEC Filing  
10/17/2016Jean Jacques BienaimeCEOSell41,666$84.39$3,516,193.74View SEC Filing  
10/14/2016Jean Jacques BienaimeCEOSell64,125$86.96$5,576,310.00View SEC Filing  
9/29/2016Jean Jacques BienaimeCEOSell53,125$93.65$4,975,156.25View SEC Filing  
9/27/2016Jeffrey Robert AjerEVPSell18,467$95.61$1,765,629.87View SEC Filing  
9/16/2016Jean Jacques BienaimeCEOSell137,368$95.34$13,096,665.12View SEC Filing  
8/26/2016Henry J FuchsEVPSell15,000$95.06$1,425,900.00View SEC Filing  
8/16/2016Jean Jacques BienaimeCEOSell41,666$91.49$3,812,022.34View SEC Filing  
8/1/2016Brian MuellerVPSell287$100.00$28,700.00View SEC Filing  
8/1/2016Daniel K SpiegelmanCFOSell4,000$99.33$397,320.00View SEC Filing  
8/1/2016George Eric DavisEVPSell2,167$100.00$216,700.00View SEC Filing  
7/27/2016V Bryan LawlisDirectorSell1,100$95.39$104,929.00View SEC Filing  
7/22/2016V Bryan LawlisDirectorSell6,400$95.01$608,064.00View SEC Filing  
7/18/2016Jean Jacques BienaimeCEOSell41,666$92.72$3,863,271.52View SEC Filing  
7/7/2016George Eric DavisEVPSell2,167$90.00$195,030.00View SEC Filing  
6/20/2016V Bryan LawlisDirectorSell550$82.77$45,523.50View SEC Filing  
6/16/2016Jean Jacques BienaimeCEOSell41,666$80.55$3,356,196.30View SEC Filing  
6/6/2016Daniel K SpiegelmanCFOSell1,649$89.14$146,991.86View SEC Filing  
5/31/2016Daniel K SpiegelmanCFOSell20,841$89.88$1,873,189.08View SEC Filing  
5/26/2016Henry J FuchsEVPSell15,000$87.81$1,317,150.00View SEC Filing  
5/23/2016Daniel K SpiegelmanCFOSell3,769$87.07$328,166.83View SEC Filing  
5/18/2016Robert BaffiEVPSell5,000$87.05$435,250.00View SEC Filing  
5/10/2016George Eric DavisEVPSell14,658$85.11$1,247,542.38View SEC Filing  
5/5/2016Jean Jacques BienaimeCEOSell50,000$80.15$4,007,500.00View SEC Filing  
5/3/2016Jeffrey Robert AjerEVPSell415$86.03$35,702.45View SEC Filing  
5/2/2016Jean Jacques BienaimeCEOSell36,500$85.01$3,102,865.00View SEC Filing  
3/14/2016George Eric DavisEVPSell1,996$86.21$172,075.16View SEC Filing  
3/4/2016Jeffrey Robert AjerSVPSell1,255$88.42$110,967.10View SEC Filing  
3/2/2016Daniel K SpiegelmanCFOSell4,623$86.12$398,132.76View SEC Filing  
3/1/2016Jean Jacques BienaimeCEOSell10,000$84.28$842,800.00View SEC Filing  
2/22/2016Michael G GreyDirectorSell7,500$80.00$600,000.00View SEC Filing  
12/16/2015George Eric DavisSVPSell1,362$100.00$136,200.00View SEC Filing  
11/30/2015Jean Jacques BienaimeCEOSell1,000$94.74$94,740.00View SEC Filing  
11/16/2015Daniel K. SpiegelmanCFOSell20,000$104.30$2,086,000.00View SEC Filing  
11/16/2015V Bryan LawlisDirectorSell8,550$106.90$913,995.00View SEC Filing  
10/15/2015Jean Jacques BienaimeCEOSell1,000$108.24$108,240.00View SEC Filing  
9/14/2015Jean Jacques BienaimeCEOSell1,000$131.43$131,430.00View SEC Filing  
7/20/2015Jeffrey Robert AjerSVPSell3,000$150.00$450,000.00View SEC Filing  
7/7/2015Jean Jacques BienaimeCEOSell1,500$139.07$208,605.00View SEC Filing  
6/5/2015Daniel K SpiegelmanCFOSell1,649$122.30$201,672.70View SEC Filing  
6/5/2015Henry J FuchsEVPSell1,864$122.32$228,004.48View SEC Filing  
6/4/2015Jeffrey Robert AjerSVPSell1,362$122.35$166,640.70View SEC Filing  
6/1/2015Daniel K SpiegelmanCFOSell5,523$124.73$688,883.79View SEC Filing  
6/1/2015Jeffrey Robert AjerSVPSell377$123.76$46,657.52View SEC Filing  
5/29/2015Daniel K SpiegelmanCFOSell1,578$126.15$199,064.70View SEC Filing  
5/26/2015Jeffrey Robert AjerSVPSell1,625$126.55$205,643.75View SEC Filing  
5/18/2015Daniel K SpiegelmanCFOSell2,059$124.77$256,901.43View SEC Filing  
5/18/2015George Eric DavisSVPSell2,558$125.26$320,415.08View SEC Filing  
5/18/2015Henry J FuchsEVPSell1,864$124.78$232,589.92View SEC Filing  
5/13/2015Henry J FuchsEVPSell1,434$121.37$174,044.58View SEC Filing  
5/11/2015Henry J FuchsEVPSell2,869$121.64$348,985.16View SEC Filing  
3/17/2015Jean Jacques BienaimeCEOSell2,000$124.17$248,340.00View SEC Filing  
3/16/2015Henry J FuchsEVPSell41,315$123.57$5,105,294.55View SEC Filing  
3/16/2015Jean Jacques BienaimeCEOSell1,000$123.48$123,480.00View SEC Filing  
3/10/2015Jean Jacques BienaimeCEOSell21,021$112.39$2,362,550.19View SEC Filing  
3/9/2015Jean Jacques BienaimeCEOSell19,000$112.13$2,130,470.00View SEC Filing  
3/5/2015Jean Jacques BienaimeCEOSell10,000$113.70$1,137,000.00View SEC Filing  
3/5/2015Robert BaffiEVPSell14,051$116.37$1,635,114.87View SEC Filing  
3/4/2015Jean Jacques BienaimeCEOSell13,916$107.92$1,501,814.72View SEC Filing  
3/3/2015Jean Jacques BienaimeCEOSell5,000$107.42$537,100.00View SEC Filing  
3/2/2015Daniel K SpiegelmanCFOSell15,500$107.00$1,658,500.00View SEC Filing  
3/2/2015George Eric DavisSVPSell23,000$108.31$2,491,130.00View SEC Filing  
3/2/2015Jean Jacques BienaimeCEOSell5,000$108.44$542,200.00View SEC Filing  
1/9/2015Jean Jacques BienaimeCEOSell2,000$94.14$188,280.00View SEC Filing  
12/24/2014Jean Jacques BienaimeCEOSell5,000$88.73$443,650.00View SEC Filing  
12/10/2014Jean Jacques BienaimeCEOSell2,000$95.00$190,000.00View SEC Filing  
12/4/2014Alan LewisDirectorSell7,500$89.90$674,250.00View SEC Filing  
12/2/2014Brian MuellerVPSell11,950$90.91$1,086,374.50View SEC Filing  
11/25/2014George Eric DavisSVPSell20,000$89.75$1,795,000.00View SEC Filing  
11/25/2014Jean Jacques BienaimeCEOSell2,000$90.00$180,000.00View SEC Filing  
11/12/2014Jean Jacques BienaimeCEOSell1,000$81.51$81,510.00View SEC Filing  
11/10/2014Henry J FuchsEVPSell20,000$86.55$1,731,000.00View SEC Filing  
11/10/2014Jean Jacques BienaimeCEOSell4,000$87.00$348,000.00View SEC Filing  
11/3/2014Jean Jacques BienaimeCEOSell3,000$85.33$255,990.00View SEC Filing  
11/3/2014Jeffrey Robert AjerSVPSell47$83.54$3,926.38View SEC Filing  
10/30/2014Robert BaffiEVPSell75,425$81.34$6,135,069.50View SEC Filing  
10/24/2014Jean Jacques BienaimeCEOSell2,000$80.00$160,000.00View SEC Filing  
9/19/2014George Eric DavisSVPSell17,536$69.75$1,223,136.00View SEC Filing  
9/2/2014Daniel K SpiegelmanCFOSell16,000$69.83$1,117,280.00View SEC Filing  
8/20/2014Jean Jacques BienaimeCEOSell5,000$70.00$350,000.00View SEC Filing  
8/5/2014Henry J FuchsEVPSell10,000$65.00$650,000.00View SEC Filing  
8/1/2014Daniel K SpiegelmanCFOSell2,229$61.76$137,663.04View SEC Filing  
7/2/2014Daniel K SpiegelmanCFOSell2,229$64.00$142,656.00View SEC Filing  
6/4/2014Jean Jacques BienaimeCEOSell2,000$61.20$122,400.00View SEC Filing  
5/22/2014Jean Jacques BienaimeCEOSell1,000$56.88$56,880.00View SEC Filing  
5/21/2014Jean Jacques BienaimeCEOSell1,545$56.19$86,813.55View SEC Filing  
5/16/2014Henry FuchsEVPSell1,864$56.86$105,987.04View SEC Filing  
5/16/2014Jeffrey Robert AjerSVPSell1,004$56.91$57,137.64View SEC Filing  
5/16/2014V Bryan LawlisDirectorSell1,700$56.87$96,679.00View SEC Filing  
5/13/2014Henry FuchsEVPSell1,434$58.23$83,501.82View SEC Filing  
5/9/2014Henry FuchsEVPSell3,479$57.91$201,468.89View SEC Filing  
2/3/2014Henry FuchsEVPSell10,000$67.70$677,000.00View SEC Filing  
12/24/2013Jean Jacques BienaimeCEOSell10,000$68.71$687,100.00View SEC Filing  
12/5/2013Jean Jacques BienaimeCEOSell5,000$69.70$348,500.00View SEC Filing  
10/16/2013Jean Jacques BienaimeCEOSell2,000$67.73$135,460.00View SEC Filing  
10/10/2013Jean Jacques BienaimeCEOSell3,000$66.76$200,280.00View SEC Filing  
9/19/2013Henry FuchsEVPSell10,000$80.19$801,900.00View SEC Filing  
9/16/2013Jean Jacques BienaimeCEOSell2,000$73.08$146,160.00View SEC Filing  
9/9/2013Robert BaffiEVPSell20,000$73.00$1,460,000.00View SEC Filing  
9/5/2013Henry J FuchsEVPSell10,000$70.00$700,000.00View SEC Filing  
9/4/2013Daniel K SpiegelmanCFOSell9,000$69.00$621,000.00View SEC Filing  
8/15/2013Jean Jacques BienaimeCEOSell1,000$64.36$64,360.00View SEC Filing  
7/1/2013Daniel K SpiegelmanCFOSell4,066$59.78$243,065.48View SEC Filing  
7/1/2013Henry J FuchsEVPSell10,000$60.00$600,000.00View SEC Filing  
6/3/2013Henry J FuchsEVPSell1,098$58.32$64,035.36View SEC Filing  
5/23/2013Henry J FuchsEVPSell20,609$66.29$1,366,170.61View SEC Filing  
5/22/2013Mark WoodVPSell3,103$67.12$208,273.36View SEC Filing  
5/21/2013Jean Jacques BienaimeCEOSell2,000$64.14$128,280.00View SEC Filing  
5/16/2013Jean Jacques BienaimeCEOSell12,000$67.90$814,800.00View SEC Filing  
5/14/2013Brian MuellerVPSell4,947$70.35$348,021.45View SEC Filing  
5/14/2013George Eric DavisSVPSell20,000$70.34$1,406,800.00View SEC Filing  
5/14/2013Jean Jacques BienaimeCEOSell15,000$70.17$1,052,550.00View SEC Filing  
5/13/2013Jean Jacques BienaimeCEOSell15,800$68.77$1,086,566.00View SEC Filing  
5/13/2013Jeffrey Robert AjerSVPSell1,248$69.26$86,436.48View SEC Filing  
5/8/2013Jean Jacques BienaimeCEOSell4,000$65.87$263,480.00View SEC Filing  
5/2/2013Jean Jacques BienaimeCEOSell3,000$64.99$194,970.00View SEC Filing  
4/10/2013Robert BaffiEVPSell20,000$64.00$1,280,000.00View SEC Filing  
3/22/2013Mark WoodVPSell3,103$60.21$186,831.63View SEC Filing  
3/4/2013George Eric DavisSVPSell4,000$60.18$240,720.00View SEC Filing  
2/22/2013Mark WoodVPSell3,103$55.22$171,347.66View SEC Filing  
2/4/2013Jean Jacques BienaimeCEOSell2,000$55.77$111,540.00View SEC Filing  
12/27/2012Jean Jacques BienaimeCEOSell17,000$48.37$822,290.00View SEC Filing  
11/12/2012George Eric DavisSVPSell99,075$48.45$4,800,183.75View SEC Filing  
9/4/2012Henry J FuchsEVPSell5,000$37.76$188,800.00View SEC Filing  
8/22/2012Mark WoodVPSell2,665$37.93$101,083.45View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for BioMarin Pharmaceutical (NASDAQ:BMRN)
Latest Headlines for BioMarin Pharmaceutical (NASDAQ:BMRN)
Source:
DateHeadline
finance.yahoo.com logoWhy Is BioMarin (BMRN) Down 2.2% Since the Last Earnings Report?
finance.yahoo.com - March 28 at 1:04 PM
americanbankingnews.com logoBioMarin Pharmaceutical Inc. (BMRN) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - March 24 at 1:34 PM
americanbankingnews.com logoBioMarin Pharmaceutical Inc. (BMRN) Downgraded by Vetr Inc. to Hold
www.americanbankingnews.com - March 19 at 4:19 PM
americanbankingnews.com logoBioMarin Pharmaceutical (BMRN) – Research Analysts’ Weekly Ratings Updates
www.americanbankingnews.com - March 16 at 2:06 PM
nasdaq.com logoCommit To Purchase BioMarin Pharmaceutical At $70, Earn 8.1% Using Options
www.nasdaq.com - March 15 at 4:17 PM
americanbankingnews.com logoBioMarin Pharmaceutical’s (BMRN) Outperform Rating Reaffirmed at Cowen and Company
www.americanbankingnews.com - March 14 at 11:30 AM
americanbankingnews.com logoJean Jacques Bienaime Sells 11,000 Shares of BioMarin Pharmaceutical Inc. (BMRN) Stock
www.americanbankingnews.com - March 13 at 10:49 PM
americanbankingnews.com logoDaniel K. Spiegelman Sells 2,303 Shares of BioMarin Pharmaceutical Inc. (BMRN) Stock
www.americanbankingnews.com - March 8 at 10:04 PM
americanbankingnews.com logoBioMarin Pharmaceutical Inc. (BMRN) EVP Sells $452,800.00 in Stock
www.americanbankingnews.com - March 8 at 10:04 PM
streetinsider.com logoBioMarin Pharma (BMRN): Takeaways From Investor Dinner
www.streetinsider.com - March 8 at 4:40 PM
streetinsider.com logoInstinet Starts BioMarin Pharmaceutical Inc. (BMRN) at Neutral - StreetInsider.com
www.streetinsider.com - March 3 at 3:21 PM
finance.yahoo.com logoCoverage initiated on BioMarin Pharm by Instinet
finance.yahoo.com - March 2 at 4:08 PM
finance.yahoo.com logoBIOMARIN PHARMACEUTICAL INC Financials
finance.yahoo.com - March 2 at 4:08 PM
biz.yahoo.com logoBIOMARIN PHARMACEUTICAL INC Files SEC form 10-K, Annual Report
biz.yahoo.com - February 27 at 11:22 AM
finance.yahoo.com logoBlog Coverage Cempra Announced Positive Results from the Phase-III Study for the Treatment of Acute Bacterial Skin and Skin Structure Infections
finance.yahoo.com - February 27 at 11:22 AM
fool.com logoBioMarin Pharmaceutical Inc. Logs a Combined Blockbuster
www.fool.com - February 25 at 3:50 PM
reuters.com logoBRIEF-Biomarin reports Q4 GAAP loss per share $0.53
www.reuters.com - February 24 at 12:59 PM
nasdaq.com logoBioMarin Pharmaceutical Breaks Below 200-Day Moving Average - Notable for BMRN
www.nasdaq.com - February 24 at 12:59 PM
seekingalpha.com logoBioMarin Pharmaceutical (BMRN) Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - February 24 at 12:59 PM
finance.yahoo.com logoEdited Transcript of BMRN earnings conference call or presentation 23-Feb-17 9:30pm GMT
finance.yahoo.com - February 24 at 12:59 PM
finance.yahoo.com logoBioMarin (BMRN) Q4 Loss Narrower than Expected; Sales Beat
finance.yahoo.com - February 24 at 12:59 PM
rttnews.com logoEARNINGS SUMMARY: Details of Biomarin Pharmaceutical Inc. Q4 Earnings Report
www.rttnews.com - February 23 at 8:54 PM
us.rd.yahoo.com logoBioMarin Announces Fourth Quarter and Full Year 2016 Financial Results
us.rd.yahoo.com - February 23 at 8:54 PM
biz.yahoo.com logoBIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
us.rd.yahoo.com - February 23 at 8:54 PM
biz.yahoo.com logoQ4 2016 Biomarin Pharmaceutical Inc Earnings Release - Time Not Supplied
biz.yahoo.com - February 23 at 3:54 PM
fool.com logo3 Biotech Stocks You May Be Overlooking
www.fool.com - February 22 at 3:57 PM
investopedia.com logoJANA Partners Made Massive New Pharma Investments in Q4
www.investopedia.com - February 21 at 3:20 PM
finance.yahoo.com logoBlog Coverage Celgene's Multiple Sclerosis Drug Reported Positive Phase-III Results
finance.yahoo.com - February 21 at 11:46 AM
fool.com logoBetter Buy: Alnylam Pharmaceuticals, Inc. vs. BioMarin Pharmaceutical Inc.
www.fool.com - February 20 at 10:13 AM
finance.yahoo.com logoBioMarin (BMRN) Q4 Earnings: Will it Post a Beat Again?
finance.yahoo.com - February 17 at 6:11 PM
nasdaq.com logoBiomarin Pharma To Participate In Leerink Partners Global Conference At 1:00 PM
www.nasdaq.com - February 16 at 4:03 PM

Social

Frequently Asked Questions for BioMarin Pharmaceutical (NASDAQ:BMRN)

What is BioMarin Pharmaceutical's stock symbol?

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

How were BioMarin Pharmaceutical's earnings last quarter?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) posted its quarterly earnings data on Thursday, February, 23rd. The company reported ($0.53) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.38) by $0.15. The business earned $300 million during the quarter, compared to analyst estimates of $296.54 million. BioMarin Pharmaceutical had a negative return on equity of 8.54% and a negative net margin of 46.22%. The firm's revenue for the quarter was up 31.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.39 EPS.

When will BioMarin Pharmaceutical make its next earnings announcement?

BioMarin Pharmaceutical is scheduled to release their next quarterly earnings announcement on Wednesday, April, 26th 2017.

What guidance has BioMarin Pharmaceutical issued on next quarter's earnings?

BioMarin Pharmaceutical issued an update on its FY16 earnings guidance on Thursday, October, 27th. The company provided earnings per share guidance of ($0.06)-(0.18) for the period, compared to the Thomson Reuters consensus earnings per share estimate of ($0.27). The company issued revenue guidance of $1.1-1.15 billion, compared to the consensus revenue estimate of $1.13 billion.

Where is BioMarin Pharmaceutical's stock going? Where will BioMarin Pharmaceutical's stock price be in 2017?

20 brokers have issued twelve-month target prices for BioMarin Pharmaceutical's shares. Their forecasts range from $84.00 to $150.00. On average, they anticipate BioMarin Pharmaceutical's share price to reach $112.05 in the next year.

What are analysts saying about BioMarin Pharmaceutical stock?

Here are some recent quotes from research analysts about BioMarin Pharmaceutical stock:

  • 1. Instinet analysts commented, "We are initiating coverage of BMRN with a Neutral rating and $93 target price. BioMarin has a strong core business, bolstered by a growing Vimizim franchise; however, we view this growth to be priced in. We continue to expect Vimizim to drive in-line revenue growth in 2017E, though we anticipate market saturation to result in slowing 2018 sales. We anticipate that upside to revenue growth from Brineura and pegvaliase will not materialize until 2H18." (3/1/2017)
  • 2. Cowen and Company analysts commented, "Q4:16 Total Rev." (2/24/2017)
  • 3. According to Zacks Investment Research, "BioMarin should continue to see growth in both its orphan disease drugs – Vimizim and Kuvan – in 2017. Robust patient growth and penetration should propel the drugs’ sales. The company’s progress with its pipeline has been impressive. Moreover, loss estimates have narrowed lately ahead of the company's Q4 results. Its stock has outperformed the Zacks classified Medical-Biomedical and Genetics industry in the past one year. However, BioMarin has suffered quite a few regulatory setbacks related to its pipeline candidates, Brineura and Kyndrisa. Delayed approvals or development setbacks could have a negative impact on the stock. Also, the company’s top line is under pressure due to political and macroeconomic instability in Brazil and the Middle East. Meanwhile, BioMarin is facing generic threat for key drug Kuvan. The earlier-than-expected entry of generics would be a huge blow for the company." (2/1/2017)

Who owns BioMarin Pharmaceutical stock?

BioMarin Pharmaceutical's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Sands Capital Management LLC (5.45%), State Street Corp (2.18%), Temasek Holdings Private Ltd (2.02%), Palo Alto Investors LLC (1.14%), Viking Global Investors LP (0.81%) and William Blair Investment Management LLC (0.64%). Company insiders that own BioMarin Pharmaceutical stock include Brian Mueller, Daniel K Spiegelman, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Michael G Grey, Robert Baffi and V Bryan Lawlis.

Who sold BioMarin Pharmaceutical stock? Who is selling BioMarin Pharmaceutical stock?

BioMarin Pharmaceutical's stock was sold by a variety of institutional investors in the last quarter, including Sands Capital Management LLC, Fred Alger Management Inc., UBS Asset Management Americas Inc., William Blair Investment Management LLC, TCW Group Inc., Teachers Advisors LLC, FIL Ltd and Ithaka Group LLC. Company insiders that have sold BioMarin Pharmaceutical stock in the last year include Brian Mueller, Daniel K Spiegelman, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Robert Baffi and V Bryan Lawlis.

Who bought BioMarin Pharmaceutical stock? Who is buying BioMarin Pharmaceutical stock?

BioMarin Pharmaceutical's stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, Viking Global Investors LP, Marshall Wace LLP, AMF Pensionsforsakring AB, Asset Management One Co. Ltd., Palo Alto Investors LLC, State Street Corp and Frontier Capital Management Co. LLC.

How do I buy BioMarin Pharmaceutical stock?

Shares of BioMarin Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of BioMarin Pharmaceutical stock cost?

One share of BioMarin Pharmaceutical stock can currently be purchased for approximately $89.58.

BioMarin Pharmaceutical (BMRN) Chart for Wednesday, March, 29, 2017

This page was last updated on 3/29/2017 by MarketBeat.com Staff